Q-omics provides the consensus-scored CAT profile across patient tissues and cancer cell-line models. CAT expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAT is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, CAT RNA expression shows 19,431 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUAD, and ACC as cancer lineages where CAT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAT survival associations across molecular data types. CAT RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAT RNA expression–survival associations across cancer types. High CAT expression shows unfavorable associations in ACC, but favorable associations in KIRC, BRCA, SKCM, THCA and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAT RNA expression.
This table summarizes CAT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CAT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAT shows lower tumor expression in LUAD, KIRP, LUSC, KIRC, COAD and BRCA. The LUAD box plot shows higher CAT RNA expression in normal versus tumor tissue (log2 FC = −2.577, t-test p < 0.001).
This table shows molecular features associated with CAT in patient tissues and cancer cell lines. In patient samples, CAT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and KIDNEY.
